You are here: Industry Insights > Perrigo

News List

Perrigo plans to separate prescription drugs business pharmatimes
August 10, 2018
Perrigo’s Board of Directors has approved a plan to separate the company's Prescription Pharmaceuticals (Rx) business, following a strategic portfolio review.
Perrigo Confirms First To File Patent Challenge for Generic Version of Ultravate Lotion, 0.05% americanpharmaceuticalreview
May 18, 2018
Perrigo announced that Sun Pharmaceutical and MiCal Pharmaceuticals initiated patent litigations on May 9 and 10, 2018, in the U.S. District Court for the District of Delaware
Perrigo Announces Final FDA Approval and Launch of an AB Rated Generic Version of Epiduo Gel biospace
January 25, 2018
Perrigo Company (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%.
Perrigo Secures API Divestiture for $110M contractpharm
November 22, 2017
Perrigo has completed its $ 110 million divestment of its API business in Israel
Alvogen Announces Acquisition of Omega Bittner americanpharmaceuticalreview
August 16, 2017
Alvogen announced today that it has signed a definitive agreement to acquire Omega Bittner, a Russia-based pharmaceutical firm owned by Perrigo Company.
Perrigo offloading its ingredient business to private equity investor for $110M fiercepharma
August 11, 2017
Perrigo, which sold this API plant in India to Strides Shasun, now has a deal to sell its Israel API business to SK Capital for $110 million.
SK Capital Acquires Perrigo Company’s API Business americanpharmaceuticalreview
August 11, 2017
SK Capital has signed a definitive agreement to acquire Perrigo API business.This acquisition complements other companies SK owns and operates in the API and FDF value chain including Noramco, Tasmanian Alkaloids and Halo Pharmaceutical, all of which will
Perrigo Launches Generic Version of Axiron americanpharmaceuticalreview
July 06, 2017
Perrigo Company announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron Topical Solution, 30 mg/1.5 mL (CIII).
US authorities search Perrigo's offices as part of drug-pricing probe firstwordpharma
May 04, 2017
Perrigo disclosed that search warrants were executed at its corporate offices as part of an ongoing investigation by the US Department of Justice Antitrust Division related to generic-drug pricing.
Perrigo to sell Tysabri drug royalty to RPI for $2.85bn pharmaceutical-technology
March 02, 2017
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma’s (RPI) affiliate RPI Finance Trust for $2.85bn.

Previous page 1 2 3 Next page